Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study
PLOS Medicine · 09.09.2025 · 22 (9) · e1004732
DOI: 10.1371/journal.pmed.1004732 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS Medicine, online erschienen am 09.09.2025. Verfasst von Kenneth K Mugwanya und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Global Health, University of Washington, Seattle, Washington, United States of America. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Anti-HIV Agents, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background Oral emtricitabine/tenofovir disoproxil fumarate (F/TDF) preexposure prophylaxis (PrEP) effectiveness against HIV acquisition highly depends on adherence. For men who have sex with men, a dosing study in the United States (US) population defined clinically meaningful tenofovir diphosphate (TFV-DP) thresholds in dried blood spots (DBS) based on the rounded 25th percentile for 2, 4, and 7 doses/week as 350, 700, and 1,250 fmol/punch. However, divergent efficacy results in the first generation randomized clinical trials of F/TDF PrEP among African women led to several hypotheses to question whether the pharmacology and adherence requirement for oral F/TDF PrEP may be different in cisgender women compared to what is already established for men. Methods and findings We conducted an open-label, parallel, randomized directly observed dosing (DOD) study of oral F/TDF PrEP among women without HIV who were not pregnant or breastfeeding in Kenya. Participants were randomly assigned to 2, 4, or 7 DOD F/TDF doses/week for 8 weeks. Blood was collected weekly, and TFV-DP and emtricitabine triphosphate (FTC-TP) concentrations in DBS and peripheral blood mononuclear cells (PBMCs) were quantified using validated liquid chromatography-tandem mass spectrometry. For DBS, concentrations were quantified from a 3-mm punch using the 70% methanol/30% water (70:30) extraction method as the primary process—the same method used for the original TFV-DP benchmarks derived in US adults, and additionally with 50% methanol/50% water (50:50) extraction using punches from the same DBS spot to compare the extraction performance of 70:30 versus 50:50 methods. The primary outcome was the steady-state fitted concentrations of TFV-DP and dose proportionality in DBS and the observed PBMC TFV-DP levels by study dosing groups. Secondary outcomes included the quantitative concentrations of FTC-TP in DBS, TFV-DP half-life in DBS, and the relative TFV-DP recovery from DBS using the 70:30 versus 50:50 extraction method. One-compartment population pharmacokinetic models were fit to estimate steady-state DBS concentrations. Descriptive statistics were summarized as range, means, and medians with interquartile range (IQR) for continuous outcomes and proportions for categorical variables. Fifty-four women were enrolled and randomized. Median age was 22 (IQR, 20–25) years. The observed median (IQR) week 8 TFV-DP concentrations in DBS were 359 (266–464), 749 (596–923), and 1,389 (1,151–1,551) fmol/punch after 2, 4, and 7 doses/week, respectively. At week 8, FTC-TP was quantifiable in 71%, 19%, and 0% DBS samples for 7, 4, and 2 doses/week groups, respectively. Fitted median (IQR) steady-state DBS TFV-DP concentrations were 416 (316, 516), 832 (631, 1,033), and 1,457 (1,106, 1,808) fmol/punch for 2, 4, and 7 doses/week, respectively, similar to previous estimates in US adults. TFV-DP exhibited a mean half-life of 17.5 days (95%CI: 16.7, 18.4) in DBS and steady-state TFV-DP concentrations varied in direct proportion to the dosing frequency [slope: 1.02 90% confidence interval 0.84, 1.20]. The 50:50 DBS extraction method yielded 1.27 (95% CI 1.25, 1.28) higher TFV-DP concentrations compared to the 70:30 method. When the 1.27 conversion factor was applied to the original 70:30 method-derived TFV-DP thresholds, the updated TFV-DP adherence interpretation benchmarks based on the 50:50 extraction were:
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Global Health, University of Washington, Seattle, Washington, United States of America.
- Department of Epidemiology, University of Washington, Seattle, Washington, United States of America.
- Kenya Medical Research Institute, Nairobi, Kenya.
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.
- Fred Hutchinson Center, Seattle, Washington, United States of America.
- University of California San Francisco, San Francisco, California, United States of America.
ORCID-Profile: Kenneth K Mugwanya, Samantha MaWhinney, Deborah Donnell, Kenneth Ngure, Clare E Brown, Elena A Rechkina, Bhavna H Chohan, Linxuan Wu, Elex Hill, Nina Akelo, Marianne Muriithi, Corwin Coppinger, Peter L Anderson
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Mugwanya, K. K., Saina, M., Mugo, N. R., MaWhinney, S., Morrow, M., Schaafsma, T. T., Donnell, D., Glidden, D. V., Ngure, K., Brown, C. E., Rechkina, E. A., Chohan, B. H., Wu, L., Hill, E., Koome, E., Akelo, N., Mbaire, S., Morrison, S. A., Kibatha, M., …, & Women Benchmark Study Team (2025). Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study. PLOS Medicine, 22(9), e1004732. https://doi.org/10.1371/journal.pmed.1004732
Vancouver
Mugwanya KK, Saina M, Mugo NR, MaWhinney S, Morrow M, Schaafsma TT, et al. Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study. PLOS Medicine. 2025;22(9):e1004732. doi:10.1371/journal.pmed.1004732
BibTeX
@article{Mugwanya2025,
author = {Mugwanya, Kenneth K and Saina, Matilda and Mugo, Nelly R and MaWhinney, Samantha and Morrow, Mary and Schaafsma, Torin T and Donnell, Deborah and Glidden, David V and Ngure, Kenneth and Brown, Clare E and Rechkina, Elena A and Chohan, Bhavna H and Wu, Linxuan and Hill, Elex and Koome, Eric and Akelo, Nina and Mbaire, Sarah and Morrison, Susan A and Kibatha, Mary and Njeru, Irene and Muriithi, Marianne and Coppinger, Corwin and Bushman, Lane and Baeten, Jared M and Anderson, Peter L and Women Benchmark Study Team, Women Benchmark Study Team},
title = {Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study},
journal = {PLOS Medicine},
year = {2025},
volume = {22},
number = {9},
pages = {e1004732},
doi = {10.1371/journal.pmed.1004732}
}
EUVIMED